| Preface |
|
xiii | |
| Section I From The 1960s To The 2010s: How Saturation Transfer Was First Discovered And Then Migrated Into Imaging |
|
|
1 Discovery of the "Saturation Transfer" Method |
|
|
3 | (6) |
|
|
|
2 Development of Chemical Exchange Saturation Transfer in Bethesda |
|
|
9 | (8) |
|
|
|
|
|
3 History of In Vivo Exchange Transfer Spectroscopy and Imaging in Baltimore |
|
|
17 | (22) |
|
|
|
3.1 Before There Was CEST |
|
|
17 | (3) |
|
3.2 Early CEST Experiments |
|
|
20 | (4) |
|
3.3 Amide Proton Transfer-Weighted MRI |
|
|
24 | (5) |
|
3.4 Expansion of the CEST Efforts |
|
|
29 | (3) |
|
3.4.1 Assaf Gilad's Recollections |
|
|
29 | (2) |
|
3.4.2 Mike McMahon's Recollections |
|
|
31 | (1) |
|
3.5 Translation to Human Scanners |
|
|
32 | (2) |
|
3.6 Active Growth in CEST |
|
|
34 | (5) |
|
4 Early Discovery and Investigations of paraCEST Agents in Dallas |
|
|
39 | (8) |
|
|
|
5 Birth of CEST Agents in Torino |
|
|
47 | (10) |
|
|
| Section II Pulse Sequence, Imaging, And Post-Processing Schemes For Detecting CEST Contrast |
|
|
6 General Theory of CEST Image Acquisition and Post-Processing |
|
|
57 | (40) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57 | (2) |
|
|
|
59 | (19) |
|
6.2.1 Low-Power Irradiation |
|
|
60 | (1) |
|
6.2.2 Sensitivity Enhancement |
|
|
61 | (2) |
|
6.2.3 High-Power Irradiation |
|
|
63 | (1) |
|
|
|
64 | (3) |
|
|
|
67 | (1) |
|
6.2.6 Utilizing texch in LTMs to Extract CEST Contrast |
|
|
68 | (2) |
|
6.2.7 Utilizing Labeling Flip Angle to Filter Contrast |
|
|
70 | (1) |
|
|
|
70 | (1) |
|
|
|
71 | (1) |
|
6.2.10 Alternative Ways for CEST Acquisition |
|
|
72 | (1) |
|
|
|
72 | (1) |
|
6.2.10.2 Steady-state CEST |
|
|
73 | (1) |
|
|
|
74 | (1) |
|
6.2.10.4 Ultrafast gradient-encoded Z-spectroscopy |
|
|
76 | (2) |
|
|
|
78 | (9) |
|
|
|
79 | (1) |
|
6.3.1.1 Using a pre-acquired B0 map |
|
|
79 | (1) |
|
6.3.1.2 Fitting Z-spectral data |
|
|
80 | (1) |
|
|
|
81 | (1) |
|
6.3.3 Integration of CEST Effect over a Range of Offsets |
|
|
82 | (1) |
|
6.3.4 Non-MTRasym Metrics |
|
|
83 | (2) |
|
6.3.5 Additional Image-Processing Steps |
|
|
85 | (1) |
|
6.3.5.1 SNR/CNR filtering |
|
|
85 | (1) |
|
6.3.5.2 Filters for image de-noising |
|
|
85 | (1) |
|
6.3.5.3 MTC-based image filtering |
|
|
86 | (1) |
|
|
|
86 | (1) |
|
|
|
87 | (10) |
|
7 Uniform-MT Method to Separate CEST Contrast from Asymmetric MT Effects |
|
|
97 | (24) |
|
|
|
|
|
|
|
7.1 Saturation of a Spin-1/2 System |
|
|
98 | (4) |
|
7.2 Uniform Saturation of a Dipolar-Coupled Spin-1/2 System |
|
|
102 | (2) |
|
7.3 Uniform-MT Methodology |
|
|
104 | (6) |
|
7.4 Application to Brain MRI |
|
|
110 | (4) |
|
7.5 Application to Knee MRI |
|
|
114 | (3) |
|
|
|
117 | (4) |
|
|
|
121 | (40) |
|
|
|
8.1 HyperCEST in the Historic Context of CEST Development |
|
|
122 | (4) |
|
8.2 Hyperpolarized Xenon NMR |
|
|
126 | (9) |
|
8.2.1 Xenon NMR Conditions Compared to Protons |
|
|
128 | (1) |
|
8.2.2 Production of Hyperpolarized Xenon |
|
|
129 | (2) |
|
8.2.3 Delivery of hp Xe and Optimized Use of Magnetization |
|
|
131 | (3) |
|
8.2.4 Fast Spectral Encoding (Gradient-Encoded CEST) |
|
|
134 | (1) |
|
8.3 Xenon Host Structures |
|
|
135 | (6) |
|
8.3.1 Tailored Host Structures: Cryptophanes |
|
|
135 | (2) |
|
8.3.2 Compartmentalization of Xenon |
|
|
137 | (1) |
|
|
|
138 | (2) |
|
|
|
140 | (1) |
|
8.4 Phospholipid Membrane Studies/Delta Spectroscopy |
|
|
141 | (2) |
|
8.5 Live Cell NMR of Exchanging Xenon |
|
|
143 | (4) |
|
|
|
147 | (14) |
| Section III DiaCEST/ParaCEST/LipoCEST Contrast Probes |
|
|
9 Current Landscape of diaCEST Imaging Agents |
|
|
161 | (32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
161 | (4) |
|
9.2 Molecules with Alkyl Amines and Amides |
|
|
165 | (1) |
|
9.3 Molecules with Alkyl Hydroxyls |
|
|
166 | (2) |
|
9.4 N-H Containing Heterocyclic Compounds |
|
|
168 | (5) |
|
9.5 Salicylic Acid and Anthranilic Acid Analogues |
|
|
173 | (3) |
|
9.6 Macromolecules with Labile Protons |
|
|
176 | (1) |
|
9.7 Fluorine and Chemical Exchange Saturation Transfer |
|
|
177 | (16) |
|
10 Evolution of Genetically Encoded CEST MRI Reporters: Opportunities and Challenges |
|
|
193 | (26) |
|
|
|
|
|
|
|
|
|
|
|
193 | (5) |
|
10.1.1 Genetically Encoded Reporter Imaging |
|
|
194 | (2) |
|
10.1.2 Genetically Encoded MRI Reporters |
|
|
196 | (2) |
|
10.2 CEST MRI Contrast Generation Mechanism |
|
|
198 | (2) |
|
10.3 Genetically Encoded CEST MRI Reporters |
|
|
200 | (8) |
|
10.3.1 Genetically Encoded CEST-Responsive Protein-Based Reporters |
|
|
203 | (1) |
|
10.3.1.1 Lysine-rich protein (LRP)-based reporter genes |
|
|
203 | (1) |
|
10.3.1.2 Arginine-rich protein (ARP)-based reporter genes |
|
|
204 | (1) |
|
10.3.1.3 Superpositively charged green fluorescent proteins |
|
|
204 | (1) |
|
10.3.2 Genetically Encoded Enzyme/Probe CEST MRI Reporter Systems |
|
|
205 | (1) |
|
10.3.2.1 Protein kinase A |
|
|
205 | (1) |
|
10.3.2.2 Herpes simplex virus type 1 thymidine kinase |
|
|
206 | (2) |
|
10.4 Genetically Encoded Hyperpolarized Xenon (129Xe) CEST MRI Reporters |
|
|
208 | (2) |
|
10.5 Considerations in Developing CEST MRI Genetically Encoded Reporters |
|
|
210 | (1) |
|
10.6 Current Challenges and Future Directions |
|
|
210 | (1) |
|
|
|
211 | (8) |
|
11 ParaCEST Agents: Design, Discovery, and Implementation |
|
|
219 | (38) |
|
|
|
|
|
|
|
|
|
219 | (3) |
|
11.1.1 History of paraCEST Agents |
|
|
219 | (3) |
|
11.2 Lanthanide-Induced Shifts |
|
|
222 | (5) |
|
11.3 T1 and T2 Considerations in the Design of paraCEST Agents |
|
|
227 | (8) |
|
11.4 Water Molecule Exchange, Proton Exchange, and CEST Contrast |
|
|
235 | (3) |
|
11.5 Modulation of Inner-Sphere Water Exchange Rates |
|
|
238 | (9) |
|
11.6 Techniques to Measure Exchange Rates |
|
|
247 | (5) |
|
11.6.1 Direct Measurement of 1H NMR Resonance Line Widths |
|
|
248 | (1) |
|
|
|
249 | (1) |
|
|
|
250 | (2) |
|
|
|
252 | (5) |
|
12 Transition Metal paraCEST Probes as Alternatives to Lanthanides |
|
|
257 | (26) |
|
|
|
|
|
|
|
257 | (3) |
|
12.2 Coordination Chemistry of Iron(II), Cobalt(II), and Nickel(II) |
|
|
260 | (3) |
|
12.3 NMR Spectra, CEST Spectra, and Imaging |
|
|
263 | (7) |
|
|
|
266 | (3) |
|
|
|
269 | (1) |
|
|
|
270 | (6) |
|
12.4.1 pH-Responsive Agents |
|
|
270 | (1) |
|
12.4.2 Redox-Responsive Agents |
|
|
271 | (3) |
|
12.4.3 Temperature-Responsive Agents |
|
|
274 | (2) |
|
12.5 Toward In Vivo Studies |
|
|
276 | (1) |
|
|
|
277 | (6) |
|
13 Responsive paraCEST MRI Contrast Agents and Their Biomedical Applications |
|
|
283 | (28) |
|
|
|
|
|
|
|
283 | (3) |
|
13.2 ParaCEST Agents That Detect Enzyme Activities |
|
|
286 | (4) |
|
13.3 ParaCEST Agents That Detect Nucleic Acids |
|
|
290 | (2) |
|
13.4 ParaCEST Agents That Detect Metabolites |
|
|
292 | (2) |
|
13.5 ParaCEST Agents That Detect Ions |
|
|
294 | (2) |
|
13.6 ParaCEST Agents That Detect Redox State |
|
|
296 | (1) |
|
13.7 ParaCEST Agents That Measure pH |
|
|
297 | (3) |
|
13.8 ParaCEST Agents That Measure Temperature |
|
|
300 | (1) |
|
13.9 Future Directions for Clinical Translation of paraCEST Agents |
|
|
301 | (10) |
|
14 Saturating Compartmentalized Water Protons: Liposome- and Cell-Based CEST Agents |
|
|
311 | (36) |
|
|
|
|
|
|
|
|
|
|
|
311 | (2) |
|
14.2 Basic Features of lipoCEST/cellCEST Agents |
|
|
313 | (12) |
|
14.2.1 Chemical Shift of Intravesicular Water Protons in Presence of Paramagnetic SR |
|
|
313 | (10) |
|
14.2.2 CEST Contrast in lipoCEST/cellCEST: Effect of Exchange Rate and Size |
|
|
323 | (1) |
|
14.2.3 Liposomes Loaded with CEST Agents |
|
|
324 | (1) |
|
|
|
325 | (22) |
|
|
|
325 | (5) |
|
|
|
330 | (6) |
|
14.3.3 Liposomes Loaded with CEST Agents |
|
|
336 | (11) |
| Section IV Emerging Clinical Applications Of CEST Imaging |
|
|
15 Principles and Applications of Amide Proton Transfer Imaging |
|
|
347 | (30) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
347 | (2) |
|
15.2 APT Imaging Principle and Theory |
|
|
349 | (3) |
|
15.3 APT Imaging of Stroke |
|
|
352 | (3) |
|
15.4 Differentiation between Ischemia and Hemorrhage |
|
|
355 | (2) |
|
15.5 APT Imaging of Brain Tumors |
|
|
357 | (3) |
|
15.6 Differentiation between Active Glioma and Radiation Necrosis |
|
|
360 | (2) |
|
15.7 Conclusions and Future Directions |
|
|
362 | (15) |
|
16 Cartilage and Intervertebral Disc Imaging and Glycosaminoglycan Chemical Exchange Saturation Transfer (gagCEST) Experiment |
|
|
377 | (22) |
|
|
|
|
|
|
|
|
|
|
|
377 | (2) |
|
16.2 Composition and Organization of Cartilage |
|
|
379 | (2) |
|
16.3 Composition and Organization of Intervertebral Disc |
|
|
381 | (2) |
|
16.4 MRI Techniques for Measuring GAG (Other than CEST) |
|
|
383 | (2) |
|
16.4.1 Gadolinium-Enhanced Imaging |
|
|
384 | (1) |
|
|
|
384 | (1) |
|
|
|
385 | (1) |
|
|
|
385 | (8) |
|
|
|
393 | (6) |
|
17 GlucoCEST: Imaging Glucose in Tumors |
|
|
399 | (28) |
|
|
|
|
|
|
|
|
|
399 | (1) |
|
17.2 Cancer Metabolism and the Warburg Effect |
|
|
400 | (2) |
|
17.3 Imaging Methods Targeting Metabolism |
|
|
402 | (1) |
|
17.4 GlucoCEST: The Concept |
|
|
403 | (2) |
|
|
|
404 | (1) |
|
|
|
404 | (1) |
|
17.5 GlucoCEST: State of the Art |
|
|
405 | (14) |
|
17.5.1 The Origins: GlycoCEST |
|
|
406 | (1) |
|
|
|
407 | (6) |
|
|
|
413 | (4) |
|
17.5.4 Alternative Technique for Glucose Detection |
|
|
417 | (2) |
|
17.6 GlucoCEST: Good Practices |
|
|
419 | (2) |
|
17.6.1 Main Magnetic Field Drifts |
|
|
419 | (1) |
|
17.6.2 Timing of Frequency Offsets |
|
|
420 | (1) |
|
17.6.3 Offset and Integration Range |
|
|
420 | (1) |
|
17.7 Conclusion: Remaining Open Questions |
|
|
421 | (6) |
|
18 Creatine Chemical Exchange Saturation Transfer Imaging |
|
|
427 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
427 | (1) |
|
18.2 Study of Energy Metabolism: 31P MRS |
|
|
428 | (2) |
|
18.2.1 31P Magnetic Resonance Spectroscopy |
|
|
428 | (1) |
|
18.2.2 31P MRS versus CEST Imaging |
|
|
429 | (1) |
|
18.3 Development of Creatine CEST |
|
|
430 | (12) |
|
18.3.1 Definition of Exchangeable CK Amine Protons and Their Exchange Rates |
|
|
430 | (1) |
|
18.3.2 CrCEST Phantom Imaging |
|
|
431 | (2) |
|
18.3.3 In Vivo CrCEST Studies of Skeletal Muscle Exercise at Ultra-High Field |
|
|
433 | (3) |
|
18.3.4 Implementation of CrCEST at Clinical-Strength Field |
|
|
436 | (2) |
|
18.3.5 Application of CrCEST in Imaging of Myocardial Metabolism |
|
|
438 | (3) |
|
18.3.6 CrCEST Application in Brain Imaging |
|
|
441 | (1) |
|
|
|
442 | (5) |
|
19 Iodinated Contrast Media as pH-Responsive CEST Agents |
|
|
447 | (20) |
|
|
|
|
|
19.1 Iopamidol as a diaCEST Agent in Preclinical Studies |
|
|
448 | (6) |
|
19.2 Iopamidol as diaCEST Agent on a Clinical MRI Scanner (3 T) |
|
|
454 | (2) |
|
19.3 lopromide as a diaCEST Agent in Preclinical Studies |
|
|
456 | (3) |
|
19.4 Iobitridol as a diaCEST Agent in Preclinical Studies |
|
|
459 | (4) |
|
|
|
463 | (4) |
| Index |
|
467 | |